预约演示
更新于：2026-06-17
Hydroxyzine Hydrochloride
盐酸羟嗪
更新于：2026-06-17
概要
基本信息
简介Hydroxyzine是一种一代抗组胺药，通常用于治疗各种过敏症状，如荨麻疹和瘙痒。它通过阻止组胺的作用来起到止痒的作用，组胺是一种在过敏反应中释放的化学物质，会引起瘙痒、肿胀和皮疹等症状。Hydroxyzine有口服和注射制剂，患者通常耐受性良好。然而，它可能会导致嗜睡、头晕和口干等副作用。作为研究和开发研究人员，需要注意的是，目前正在研究Hydroxyzine在治疗焦虑症方面的潜在用途，因为它在临床前研究中展示出一些抗焦虑的作用。 |
药物类型 小分子化药 |
别名 Hychotine、Hydroxine、Hydroxizine + [13] |
作用方式 拮抗剂 |
作用机制 H1 receptor拮抗剂(组胺H1受体拮抗剂) |
非在研适应症 |
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H29Cl3N2O2 |
InChIKeyANOMHKZSQFYSBR-UHFFFAOYSA-N |
CAS号2192-20-3 |
关联
40
项与 盐酸羟嗪 相关的临床试验JPRN-jRCT1061250070
Efficacy of Paracervical Block During Intracavitary Brachytherapy for Cervical Cancer -Randomized Double Blind Crossover Trial -
NCT07031206
Investigating Pre-Procedural Anxiety and Effect of Analgesia on Intrauterine Device Placement and Endometrial Biopsy
CTRI/2024/10/074754
A Prospective Non-comparative Real-World Observational effectiveness and tolerability Study of Hydroxyzine Hydrochloride 50mg Sustain Release formulation for the management of Chronic Pruritus - Atarax SR
100 项与 盐酸羟嗪 相关的临床结果
登录后查看更多信息
100 项与 盐酸羟嗪 相关的转化医学
登录后查看更多信息
100 项与 盐酸羟嗪 相关的专利（医药）
登录后查看更多信息
1,361
项与 盐酸羟嗪 相关的文献（医药）2026-06-01International Journal of Clinical Oncology
Efficacy of bepotastine compared with hydroxyzine in preventing rituximab-induced infusion-related reactions in non-hodgkin lymphoma patients: a phase II, double-blind, multicenter, and randomized trial
Article
作者: Kitahiro, Yumi ; Iida, Kotaro ; Takahashi, Masako ; Murase, Natsuko ; Shimoyama, Manabu ; Harima, Isamu ; Yamamoto, Kazuhiro ; Kurata, Keiji ; Kitao, Akihito ; Minami, Hironobu ; Sakai, Rina ; Yakushijin, Kimikazu ; Okazoe-Hirakawa, Yuri ; Sugimoto, Takeshi ; Itohara, Kotaro ; Takakura, Hidetomo ; Okuno, Mamoru ; Yano, Ikuko ; Omura, Tomohiro ; Kitamura, Naoko ; Saeki, Miki
Abstract:
Background:
This study evaluated the efficacy of hydroxyzine and bepotastine, first- and second-generation H1 receptor antagonists (H1RA), as pretreatments to prevent infusion-related reactions (IRRs) during the initial rituximab infusion in patients with non-Hodgkin lymphoma.
Methods:
In this double-blind, multicenter, randomized phase II study, 40 patients received hydroxyzine or bepotastine with acetaminophen 30 min before rituximab infusion. Primary endpoint was incidence of ≥ grade 2 IRRs based on the National Cancer Institute Common Terminology Criteria for Adverse Events. Secondary endpoints included IRRs severity, time to IRR onset, and H1RA-induced drowsiness.
Results:
Incidence of ≥ grade 2 IRRs was 52.4% and 31.6% for the hydroxyzine (n = 21) and bepotastine (n = 19) groups, respectively (
P
= 0.184). Distribution of initial and maximum IRR grades in the two groups was not statistically significant (
P
= 0.846 and 0.555). Median time (range) to IRR onset in the two groups was 67 (12–112) and 62 (10–119) min, respectively (
P
= 0.981). Median visual analog scale score (range and 75th percentile) for drowsiness was 37 (0–100, 46) and 12 (0–100, 29) mm in the two groups, respectively (
P
= 0.138). Incidence of ≥ grade 2 IRRs in the absence of bone marrow infiltration was 43.8% and 14.3% in the two groups, respectively (
P
= 0.118), and no group differences were observed with bone marrow infiltration.
Conclusions:
Bepotastine did not show significant superiority over hydroxyzine in preventing rituximab-induced IRRs due to the small sample size. Nevertheless, this exploratory study provides insight for further confirmatory studies.
Trial registration number and date of registration:
jRCTs051220169; February 14, 2023.
2026-05-01Hospital pediatrics
Analyzing Incidence and Risk Factors for Delirium in Non–Intensive Care Pediatric Patients
Article
作者: Knapp, Kyle ; George, Simi ; Beam, Nicholas ; Dean, Larissa ; Andersen, Nicholas J. ; Leingang, Brett
OBJECTIVES:
Our study aimed to identify the incidence of delirium in the inpatient setting outside of intensive care and recognize potential risk factors for delirium.
METHODS:
We conducted a single-center retrospective study analyzing patients on general pediatric floors between September 2022 and January 2024 who screened positively using the Cornell Assessment of Pediatric Delirium (CAPD) tool. Delirium diagnosis was attested by a 2-person clinical team based on the DSM-5 criteria using retrospective clinical data. Incidence of delirium was calculated from the patient population with positive CAPD scores. A logistic regression model was used to assess the association between clinical delirium diagnosis and potential clinical risk factors.
RESULTS:
Of 245 patients with positive CAPD scores, 83 (33.9%) were deemed to have delirium through retrospective medical record review. Of those 83 patients, only 11 (13.3%) were diagnosed with delirium during their stay. Factors associated with increased odds of delirium included exposure to midazolam, diphenhydramine, hydroxyzine (odds ratios [ORs] of 2.59 [95% CI, 1.47–4.56], 3.4 [95% CI, 1.59–7.30], and 4.3 [95% CI, 1.42–13.0], respectively), diagnosis of sepsis (OR, 3.15; 95% CI, 1.46–6.81), and length of stay (LOS) greater than 5 days (OR, 1.90; 95% CI, 1.11–3.26).
CONCLUSIONS:
Approximately one-third of patients who screened positive for delirium on the pediatric medical floor had symptoms consistent with delirium. Sepsis, LOS greater than 5 days, and exposures to specific sedatives and antihistamines are risk factors for developing delirium. Future research may focus on improving screening and understanding the role of risk factors in delirium.
2026-04-07Retinal cases & brief reports
Uveal Effusion and Exudative Macular Detachment Secondary to SSRI and Dexamphetamine Overdose
Article
作者: Evie, Hosannah ; Mayeda, Maxwell S ; Moore, Julia C ; Gill, Zafar ; Suggs, Melissa ; Cole, Emily D
Purpose::
To report a case of unilateral choroidal effusion and exudative macular detachment following intentional overdose involving paroxetine and dexamphetamine in an adolescent patient.
Methods::
A 14-year-old female with obsessive-compulsive disorder (OCD) and attention deficit/hyperactivity disorder (ADHD), taking paroxetine, dexamphetamine, guanfacine, and hydroxyzine, was admitted with serotonin syndrome and anticholinergic toxicity following ingestion of multiple medications. Two days later, she developed acute unilateral vision loss.
Results::
Examination revealed global choroidal effusions and a serous macular detachment in the left eye, confirmed by optical coherence tomography (OCT) and B-scan ultrasonography. Fluorescein angiography (FA) showed late macular pooling without focal leakage. All systemic medications were discontinued upon admission. Over 6 weeks, the exudative detachment resolved, and visual acuity improved from 20/800 to 20/60. At 7 months, vision remained stable at 20/60, with complete anatomical resolution of subretinal fluid with near complete resolution of ellipsoid zone (EZ) attenuation on OCT.
Conclusions::
Overdose of selective serotonin reuptake inhibitors (SSRIs) has been associated with uveal effusion syndrome, and amphetamine-based stimulant use has been implicated in the development of central serous chorioretinopathy (CSCR). In this case, polypharmacy and overdose were associated with unilateral exudative retinal detachment and choroidal effusion, which resolved after discontinuing the offending agents.
16
项与 盐酸羟嗪 相关的新闻（医药）2026-04-21
100 项与 盐酸羟嗪 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 抑郁症 | 日本 | 1965-09-30 | |
| 湿疹 | 日本 | 1965-09-30 | |
| 恶心和呕吐 | 日本 | 1965-09-30 | |
| 焦虑症 | 美国 | 1956-04-12 | |
| 瘙痒 | 美国 | 1956-04-12 | |
| 荨麻疹 | 美国 | 1956-04-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 60 | (Regimen 1) | 遞鑰積鏇窪鏇製積顧願(鹽窪獵廠鑰廠壓繭顧淵) = 願衊築淵顧餘醖顧繭網 鏇鹹構艱積糧範簾夢鹹 (鑰網憲製簾餘積鹹鑰鹽, 襯積範齋淵餘願鑰鏇糧 ~ 觸衊鏇夢範糧遞艱願窪) 更多 | - | 2024-10-02 | ||
(Regimen 2) | 遞鑰積鏇窪鏇製積顧願(鹽窪獵廠鑰廠壓繭顧淵) = 獵選壓憲積醖淵齋網顧 鏇鹹構艱積糧範簾夢鹹 (鑰網憲製簾餘積鹹鑰鹽, 獵窪觸鬱衊鏇遞鹽繭網 ~ 觸膚艱繭鑰顧壓顧鑰願) 更多 | ||||||
临床4期 | 37 | (Midazolam, Hydroxyzine, Meperidine) | 糧醖鑰餘醖鏇簾範簾餘 = 襯壓範簾簾選鏇糧鬱鹽 壓餘遞壓獵築憲鑰構壓 (積鏇淵獵餘獵淵襯膚鏇, 膚壓範壓積範獵顧醖憲 ~ 觸願繭憲鑰襯襯鏇鹽齋) 更多 | - | 2023-12-05 | ||
(Midazolam, Hydroxyzine) | 糧醖鑰餘醖鏇簾範簾餘 = 鬱蓋範鹹鏇願鑰廠觸範 壓餘遞壓獵築憲鑰構壓 (積鏇淵獵餘獵淵襯膚鏇, 獵顧膚鹽積構範網積衊 ~ 選鹽齋齋築鹽鏇齋淵網) 更多 | ||||||
临床4期 | 26 | 鏇齋糧鹽襯鑰夢鹹鹹糧(構蓋鏇鹹憲構窪築繭獵) = 鬱鹹獵簾鑰艱窪築艱鏇 憲繭觸夢觸壓鏇積鬱鏇 (顧獵獵鑰齋遞蓋願鹽衊, 2.37) 更多 | - | 2023-03-03 | |||
N/A | 10 | placebo+naloxone (Placebo) | 鹽鏇繭製觸衊餘襯餘觸(築簾選積築鹽憲鹹鹽鑰) = 鬱遞蓋蓋構簾鹹衊衊壓 觸艱鬱艱蓋蓋鬱鬱鹽餘 (積鹹蓋構餘簾壓鏇鬱築, 0.76) 更多 | - | 2017-06-05 | ||
(Palonosetron) | 鹽鏇繭製觸衊餘襯餘觸(築簾選積築鹽憲鹹鹽鑰) = 衊網艱壓鑰獵網憲構簾 觸艱鬱艱蓋蓋鬱鬱鹽餘 (積鹹蓋構餘簾壓鏇鬱築, 0.37) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用